The epidermal growth factor receptor protein is involved in cell signaling pathways that control cell division and survival. Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor egfr exon 19 deletion 19del and exon 21 l858r mutation l858r are highly. Nov 11, 2008 the efficacy of epidermal growth factor receptor egfr tyrosine kinase inhibitors in nonsmall cell lung cancer nsclc has been linked to activating mutations in the egfr gene. Mutations in epidermal growth factor receptor have been discovered in association with some lung cancers.
The epidermal growth factor receptor egfr gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. The significance of epidermal growth factor receptor uncommon. Epidermal growth factor receptor egfr in lung cancer. Prevalence of the epidermal growth factor receptor mutations in lung.
Epidermal growth factor receptor mutations and gene. The aim of the present study was to investigate the mutation rate of the epidermal growth factor receptor egfr in nonsmall cell lung cancer nsclc patients and to apply logistic regression. A, structure of the kinase domain of egfr in complex with erlotinib based on protein data bank pdb accession code 1m17 and location of the most common egfr mutations. The implications of egfr mutations in patients treated with egfr inhibitors plus firstline chemotherapy are unknown. Structural, biochemical, and clinical characterization of. Mutations in the epidermal growth factor receptor and in. Lung cancers with egfr gene mutations tend to respond to treatments that. To gain further insights in the role of egfr in lung carcinogenesis, we sequenced exons 1821 of the tyrosine kinase domain using total rna extracted from. However, egfr exon 20 insertion mutations 10% of all egfr mutations are generally associated with insensitivity to available tkis gefitinib, erlotinib, and. Purpose epidermal growth factor receptor egfr mutations have been associated with tumor response to treatment with singleagent egfr inhibitors in patients with relapsed. Mutations in the epidermal growth factor receptor and in kras. Each codon of representative mutations was mapped on the protein sequence of the egfr kinase domain. Epidermal growth factor receptor egfr gene mutation. Comparison of epidermal growth factor receptor mutations between.
Thus, early detection of the egfr mutation rate and its associated factors in lung tumors. We examined 161 patients with primary lung adenocarcinoma to detect egfr expression in lung cancer cells using immunohistochemistry and determined the correlations of egfr. Previous reports have been based mainly on diagnostic screening by sequencing. Epidermal growth factor receptor egfr is expressed in 50% of. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non. Screening for epidermal growth factor receptor mutations in lung cancer. Treatment with egfr tyrosine kinase inhibitors tkis is the standard of care for molecularly selected egfr mutant patients, while its role in unselected lung cancer patients is nowadays controversial. Dec 18, 20 epidermal growth factor receptor egfr gene mutations g719x, exon 19 deletionsinsertions, l858r, and l861q predict favorable responses to egfr tyrosine kinase inhibitors tkis in advanced nonsmall cell lung cancer nsclc. Erbb2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon heterodimerization with other family members such as egfr. Clinical characteristics and survival outcomes for nonsmall. Activating mutations in the epidermal growth factor receptor gene egfr confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced nonsmallcell lung cancer. The probing of the nsclc kinome has identified numerous nonoverlapping driver genomic events, including epidermal growth factor receptor egfr gene mutations. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptormutated lung adenocarcinoma.
The impact of epidermal growth factor receptor mutations. Investigation of the epidermal growth factor receptor. Cancer structural, biochemical, and clinical characterization of epidermal growth factor receptor egfr exon 20 insertion mutations in lung cancer hiroyuki yasuda,1,2 eunyoung. The efficacy of epidermal growth factor receptor egfr tyrosine kinase inhibitors in nonsmall cell lung cancer nsclc has been linked to activating mutations in the egfr. Circulating tumor cells ctcs harvested from the csf, using cellsearch technology, are used for arms analysis. Structure of the epidermal growth factor receptor egfr protein and frequency of egfr mutations in lung cancer by a compilation of recent large studies. Mutations of the epidermal growth factor receptor gene in. Screening for epidermal growth factor receptor mutations in. Mutations in the egfr gene are more common in nsclc tumors with. Cancer structural, biochemical, and clinical characterization of epidermal growth factor receptor egfr exon 20 insertion mutations in lung cancer hiroyuki yasuda,1,2 eunyoung park,3 caihong yun,4 natasha j. Rapid detection of epidermal growth factor receptor. Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor egfr exon 19 deletion 19del and exon 21 l858r mutation l858r are highly correlated with sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor egfrtki treatment in nonsmallcell lung cancer nsclc. Lung cancers with egfr gene mutations tend to respond to treatments that specifically target the overactive epidermal growth factor receptor protein that allows cancer cells to constantly grow and divide.
Not all epidermal growth factor receptor mutations in lung. Lung cancer is the leading cause of deaths worldwide, including in taiwan. Costa division of hematologyoncology, department of medicine, beth israel deaconess medical center. The probing of the nsclc kinome has identified numerous nonoverlapping driver genomic events, including epidermal growth factor receptor. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcimona by highresolution meltiong amplicon analysis. A, structure of the kinase domain of egfr in complex with erlotinib based on protein data bank pdb. However, the relevance of differentially located egfr proteins in lung cancer remains unclear.
A seminal study found that 57% of gbm specimens contain a mutation, rearrangement. Prognostic value of localization of epidermal growth. Clinical and biological features associated with epidermal. Nodular groundglass opacities nggo are a specific type of lung adenocarcinoma.
Recently it has been reported that mutations in the tyrosine kinase domain of the epidermal growth factor receptor egfr gene occur in a subset of patients with lung cancer showing a dramatic response to egfr tyrosine kinase inhibitors. In patients with advanced lung adenocarcinoma, those harboring egfr mutations have longer. Mutations of the epidermal growth factor receptor egfr in patients with nonsmall cell lung cancer nsclc were identified by resequencing all exons of this gene to evaluate the. Somatic mutations in the kinase domain of the epidermal growth factor receptor egfr gene are detected in approximately 40% and 17% of lung adenocarcinoma in asians 1 and in caucasians, 2 respectively. Intratumoral heterogeneity is a key factor in the poor therapeutic success for gbm. Lung adenocarcinomas with mutated epidermal growth factor receptor have significant responses to tyrosine kinase inhibitors, although for unselected patients it does not appear to have a survival benefit. There is only limited data on the prevalence of epidermal growth factor receptor egfr activating mutations in squamous cell carcinomas and adenosquamous. There are many complex and rare mutations in the epidermal growth factor receptor egfr gene in nonsmall cell lung cancer nsclc other than the two classical. Pdf epidermal growth factor receptor egfr mutations in. Epidermal growth factor receptor mutations in nonsmall cell. Identification of epidermal growth factor receptor. Miliary metastases are associated with epidermal growth. Most cases of nonsmallcell lung cancer nsclc with dramatic responses to ge. In 2004, several investigators reported that somatic mutations in the epidermal growth factor receptor gene were associated with clinical responses to erlotinib and gefitinib in.
However, sequencing is a timeconsuming and complicated procedure, not suitable for routine clinical use. So far these mutations have been extensively characterized in established cell lines. Metformin plus tyrosine kinase inhibitors in epidermal growth. The aim of this study was to determine the effects of egfr mutations on downstream signaling in human tumor specimens. Mutations in the tyrosine kinase tk domain of the epidermal growth factor receptor egfr gene in lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit. Despite tremendous progress in the last decade, lung adenocarcinoma still represents a tumor with unfavorable prognosis when detected at.
A bloodbased test for epidermal growth factor receptor. Targeted therapy for these lung cancers has been established based on evidence regarding mainly common mutations. A, structure of the kinase domain of egfr in complex with erlotinib based on protein data bank. Sometimes, mutations changes in the egfr gene cause epidermal growth factor receptor proteins to be made in higher than normal amounts on some types of cancer cells. Somatic mutations in the epidermal growth factor receptor egfr gene are present in approximately 20% in caucasians to 40% in east. Pdf epidermal growth factor receptor egfr mutations in lung. In 2004, several investigators reported that somatic mutations in the epidermal growth factor receptor gene were associated with clinical responses to erlotinib and gefitinib in patients with nonsmall cell lung cancer.
Additional genetic, environmental, and lifestyle factors contribute to a persons cancer risk. When these biomarkers were first developed, early studies simplified the complexity of tumor genotype by dichotomizing them as mutant or wild type. Treatment of epidermal growth factor receptor mutations in non. However, the role of such mutations in the pathogenesis of lung cancers is unclear. The 5year overall survival os rate of advancedstage lung cancer is less than 20%. Epidermal growth factor receptor egfr gene mutations are important for the pathogenesis of lung adenocarcinoma, and the tyrosine kinase function of egfr is a promising target for the. Epidermal growth factor receptor egfr mutations in nonsmallcell lung cancer nsclc. Sometimes, mutations changes in the egfr gene cause epidermal.
Since then, multiple groups have examined the biological properties that such mutations confer as well as the clinical relevance of these mutations in patients with non. Activating mutations in the epidermal growth factor receptor gene egfr confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients. Pdf screening for epidermal growth factor receptor. Rapid detection of epidermal growth factor receptor mutations. Malignant pleural effusions mpes are often observed in lung cancer, especially adenocarcinoma.
Mutations of the epidermal growth factor receptor egfr gene in nonsmallcell lung cancer nsclc patients predict the patients who will respond to egfr. The purpose of this study was to retrospectively compare the volume doubling time vdt on serial computed tomography ct of nonsmallcell lung cancer nsclc with epidermal growth factor receptor egfr mutation with that of nsclc without the mutation. Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the middle east region. The purpose of this study was to retrospectively compare the volume doubling time vdt on serial computed tomography ct of nonsmallcell lung cancer nsclc with. Costa division of hematologyoncology, department of. Rare and complex mutations of epidermal growth factor. Epidermal growth factor receptor egfr mutations in lung cancer.
Definition of epidermal growth factor receptor nci. Treatment of epidermal growth factor receptor mutations in. Biological and clinical implications takayuki kosaka. Recently it has been reported that mutations in the tyrosine kinase domain of the epidermal growth factor receptor egfr gene occur in a subset of patients with lung cancer. Pdf lung cancer leads cancerrelated mortality worldwide. Jun 20, 2016 somatic mutations in the epidermal growth factor receptor egfr gene are present in approximately 20% in caucasians to 40% in east asians of adenocarcinomas of the lung. Screening for epidermal growth factor receptor mutations. Epidermal growth factor receptor egfr gene mutations are usually. Epidermal growth factor receptor mutations in lung cancer.
The epidermal growth factor receptor egrf in lung cancer. Uncommon epidermal growth factor receptor egfr mutations collectively account for 10% of egfr mutations, harboring heterogeneous molecular alterations within exons 1821 with. Epidermal growth factor receptor egfr is a transmembrane protein that is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor. Furthermore, the epidermal growth factor receptor egfr gene mutation is a predictor of gefitinib sensitivity in lung cancer 7,8. Epidermal growth factor receptor mutations in lung adenocarcinoma. Prognostic value of localization of epidermal growth factor. Epidermal growth factor receptor mutation analysis in tissue. Epidermal growth factor receptor mutations in lung adenocarcinoma in. A positive response to gefitinib in nonsmall cell lung cancer nsclc has been correlated to mutations in epidermal growth factor receptor egfr gene. However, gefitinib is a drug that exhibits improved efficacy and safety in locally advanced or metastatic nsclc patients. Jun 28, 2018 the nuclear translocation of epidermal growth factor receptor egfr has been considered to play a role in carcinogenesis.
Epidermal growth factor receptor egfr gene mutations g719x, exon 19 deletionsinsertions, l858r, and l861q predict favorable responses to egfr tyrosine kinase. Feb 12, 2017 treatment of epidermal growth factor receptor mutations in nonsmall cell lung cancer. The discovery that sensitizing epidermal growth factor receptor egfr mutations are predictive for therapeutic benefit from egfr tyrosine kinase inhibitors tkis such as erlotinib marked the. This study assesses different technologies for detecting epidermal growth factor receptor egfr mutations from circulating tumor dna in patients with egfr t790m. There are many complex and rare mutations in the epidermal growth factor receptor egfr gene in nonsmall cell lung cancer nsclc other than the two classical mutations of l858r and exon 19 deletional mutation.
Nonsmallcell lung cancer nsclc, the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced stages, and available systemic therapies are mostly palliative. The impact of epidermal growth factor receptor mutations on. Epidermal growth factor receptor gene mutations in nonsmallcell lung cancer cells are associated with increased radiosensitivity in vitro bo xie, liyue sun, yanjun cheng, juan zhou, jihua zheng, weimin zhang department of oncology, guangzhou general hospital of guangzhou military command, guangzhou, guangdong, peoples republic of china introduction. Screening for epidermal growth factor receptor mutations in lung cancer article pdf available in new england journal of medicine 36110. Full text epidermal growth factor receptor gene mutations. The significance of epidermal growth factor receptor. Clinical characteristics and survival outcomes for non. Epidermal growth factor receptor gene mutations in nonsmallcell. Advanced nonsmallcell lung cancer nsclc is the leading cause of cancer related deaths in the world. Biological and clinical implications takayuki kosaka, 1,3yasushi yatabe,2 hideki endoh, hiroyuki kuwano,3 takashi takahashi,4 and.
Epidermal growth factor receptor mutation as a risk factor. Epidermal growth factor receptor, lung cancer, tyrosine kinases inhibitor. Original article from the new england journal of medicine screening for epidermal growth factor receptor mutations in lung cancer. Egfr mutations were found in 350 of 2105 patients 16. There is still lack of specific biomarkers in predicting the radiosensitivity of nonsmall cell lung cancer nsclc patients in clinic.
Frequent epidermal growth factor receptor gene mutations. Update on epidermal growth factor receptor mutations in. Multicentre prospective phase ii trial of gefitinib for advanced nonsmall cell lung cancer with epidermal growth factor receptor mutations. Epidermal growth factor receptor egfr gene mutations are important for the pathogenesis of lung adenocarcinoma, and the tyrosine kinase function of egfr is a promising target for the treatment of nonsmall cell lung cancer. Cancer research 64, 89198923, december 15, 2004 mutations of the epidermal growth factor receptor gene in lung cancer. Epidermal growth factor receptor mutations in nonsmall. Epidermal growth factor receptor egfr mutation represents a good response to egfrtyrosine kinase inhibitor and an advantageous prognostic factor in advancedstage non. Genetic profiling and epidermal growth factor receptordirected. Epidermal growth factor receptor activating mutations in. Alk rearrangements and driver mutations such as egfr and kras are. Epidermal growth factor receptor egfr is expressed in 50% of nsclcs, and its expression is.
Mutations of the epidermal growth factor receptor egfr in patients with nonsmall cell lung cancer nsclc were identified by resequencing all exons of this gene to evaluate the frequencies of egfr gene mutation and identify rare or novel egfr mutations. Clinical course of patients with nonsmall cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Structure of the epidermal growth factor receptor egfr protein and frequency of egfr mutations in lung cancer by a compilation of recent. The discovery that somatic mutations in the epidermal growth factor receptor egfr gene are found in a. Schematic diagram of reported mutations in egfr in nsclc tumors. Nonsmallcell lung cancer nsclc, the most prevalent subtype of this recalcitrant cancer. Epidermal growth factor receptor gene mutations in nonsmallcell lung cancer cells are associated with increased radiosensitivity in vitro bo xie, liyue sun, yanjun cheng, juan zhou. Uncommon epidermal growth factor receptor egfr mutations collectively account for 10% of egfr mutations, harboring heterogeneous molecular alterations within exons 1821 with clinically variable responses to egfr tyrosine kinase inhibitors tkis in advanced nonsmall cell lung cancer nsclc patients. Not all epidermal growth factor receptor mutations in lung cancer are. Somatic mutations in the kinase domain of the epidermal growth factor receptor egfr gene are detected in approximately 40% and 17% of lung adenocarcinoma in asians 1. Mutations in the tyrosine kinase tk domain of the epidermal growth factor receptor egfr gene in lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit egfr kinase activity.
10 507 291 769 1377 58 1232 1267 725 450 553 1372 826 787 1301 1193 181 1370 743 160 1068 625 1401 496 86 613 730 1279 2 497 1130 540 308 1113 1050 304 1084